Circulating Biomarkers in Young Individuals with Low Peak FEV1

It is now well established that there is a range of lung function tralectories throughout the life course (1, 2). Specifically, 4-12% of young adults in the general population never achieve normal peak lung function, as determined by FEV, measurement (3). These individuals are at higher risk of developing chronic obstructive pulmonary disease (COPD) in adulthood (4), suffer a higher prevalence and a decade earlier incidence of cardiovascular and metabolic disorders, and die prematurely (3, 5). The biological mechanisms underlying these observations are unknown.
Autores: Nuria Olvera 1,2, Sandra Casas 1,2, Judith M. Vonk 3,4, Tamara Garcia 1,2, H. Marike Boezen 3,4, Maarten van den Berge 4, Alvar Agusti 1,2,5,6, and Rosa Faner 1,2,5*
Puedes leer el artículo completo aquí: https://www.atsjournals.org/doi/abs/10.1164/rccm.202205-0855LE?role=tab
Noticias relacionadas

Human senescent fibroblasts trigger fibrogenic reaction in the lungs of immunodeficient mice
A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as «Aging (Albany NY)» and «Aging-US» by Web of Science) Volume 15, Issue 14, entitled, «Human senescent fibroblasts trigger progressive lung fibrosis in mice.»

COPD and multimorbidity: recognising and addressing a syndemic occurrence
Most patients with chronic obstructive pulmonary disease (COPD) have at least one additional, clinically relevant chronic disease. Those with the most severe airflow obstruction will die from respiratory failure, but most patients with COPD die from non-respiratory disorders, particularly cardiovascular diseases and cancer.

Blood Immunophenotypes of Idiopathic Pulmonary Fibrosis: Relationship with Disease Severity and Progression
The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial.
Más artículos
COPD
- Leonardo M Fabbri et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence
- Singh D, Criner GJ, Agustí A et al. Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
- Alvar Agusti, M.D., Ph.D. – Biologics for COPD — Finally Here
- D. Pellegrino, S. Casas-Recasens, R. Faner, P. Palange, A. Agusti. When GETomics meets aging and exercise in COPD
- Alvar Agustí et al.- GOLD 2023: What’s New, Doc?
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría EPOC en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imagen obtenida en Canva Pro el 21 de junio de 2023